Cyclophilin Inhibitors for Chronic Pancreatitis

Lead Participant: CYPRALIS LIMITED

Abstract

Chronic pancreatitis is a severely painful inflammation of the pancreas that frequently requires admission to hospital and prevents normal life. Currently there is no drug treatment that affects the course of chronic pancreatitis and patients are typically treated only to alleviate their pain. As the disease progresses the pancreas undergoes degradation, along with fibrosis, which can lead to malnutrition, and also diabetes. Cypralis has identified compounds that can prevent degradation of pancreatic tissue and, separately, compounds which can inhibit signs of fibrosis. The current project is designed to test compounds to find examples that possess both activities. These compounds will be tested for activity in models of chronic pancreatitis. This project will set the stage for an advanced drug discovery project to find a drug that can prevent this serious disease from progressing further.

Lead Participant

Project Cost

Grant Offer

CYPRALIS LIMITED £118,479 £ 71,087
 

Participant

SELCIA LIMITED
UNIVERSITY OF LIVERPOOL
UNIVERSITY OF LIVERPOOL £80,000 £ 80,000
INNOVATE UK

Publications

10 25 50